Pharmaceuticals
Kintor Pharmaceutical Announces Dosing of First Batch of Subjects in Phase I Clinical Trial of GT20029 in China
SUZHOU, China, July 28, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company has dosed the first batch of subjects in its phase I clinical trial of...
2021-07-28 13:47
5713
I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange
SHANGHAI and GAITHERSBURG, Md., July 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that onJuly 27, 2021, the Board of Directors of the Comp...
2021-07-27 20:35
12065
PharmAbcine to Present at H.C Wainwright Ophthalmology Virtual Conference
DAEJEON, South Korea, July 26, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the company is invited to deliver a video presentation at H.C Wainwright Ophthalmolo...
2021-07-26 20:00
1964
HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO Congress 2021
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, July 26, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced that the abstract detailing clinical data from its Australian phase I study of next-generation anti-CTLA-4 antibody in patients with advanced solid tumo...
2021-07-26 19:11
5363
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day
SYDNEY, July 21, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on research from industry, academia, and government in order ...
2021-07-21 22:00
12276
Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody Immunotherapy
* Kineta to leverage Samsung Biologics' development and manufacturing expertise to advance KVA12.1 to IND * Samsung Biologics San Francisco R&D center and South Korea headquarters to offer a seamless, end-to-end CDMO service INCHEON, South Korea and SEATTLE, July 20, 2021 /PRNewswire/ -- Sams...
2021-07-20 20:00
2185
Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay
SUZHOU, China, July 16, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced thatParaguay's Ministry of Public Health and Social Welfare (MSPBS) has granted an emerg...
2021-07-16 14:41
37098
Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function
MELBOURNE, Australia, July 15, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced thatMovement Disorders, the official jou...
2021-07-15 21:52
37410
Kintor Pharmaceutical Collaborates with Fosun Pharma Development to Commercialise Proxalutamide for Treatment of COVID-19 in India and Africa
SUZHOU, China, July 14, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) today announced that it has entered into a licensing agreement with Shanghai Fosun Pharmaceutical Development Ltd. ("Fosun Pharma Development"), on the commercialisation of proxalutamide for the treatment of CO...
2021-07-15 10:00
34630
Johnson & Johnson Innovation announces extension of innovation partnering office at Monash University in collaboration with Victorian State Government to accelerate the life-sciences hub
- Victorian State Government extends financing of JJIPO@Monash for an additional two years - Extension will further boost Victorian hub for researchers and early-stage companies to connect with industry experts and deliver novel healthcare solutions MELBOURNE, Australia, July 15, 2021 /PRNewswi...
2021-07-15 10:00
2008
Nippon Express Italia Acquires GDP Certification for Company-owned Warehouse near Milan Malpensa Airport
TOKYO, July 14, 2021 /PRNewswire/ -- Nippon Express Italia S.P.A. (hereinafter " NE Italy"), a local subsidiary of Nippon Express Co., Ltd., obtained Good Distribution Practice (GDP) certification from the certification body CERTIQUALITY S.r.l., effectiveMay 25, for its company-owned warehouse nea...
2021-07-14 15:00
1868
Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne
SUZHOU, China, July 13, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small-molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug...
2021-07-14 07:05
18528
Kintor Pharmaceutical Announced FDA Has Greenlighted Pyrilutamide's Phase II Clinical Trial for Androgenetic Alopecia in the US
SUZHOU, China, July 11, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has greenlighted pyrilutamide's phase...
2021-07-11 21:03
20439
I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms
SHANGHAI and GAITHERSBURG, Md., July 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the signing of two new collaborations with emerging biote...
2021-07-09 20:00
30561
Sequanta and Mission Bio announce strategic partnership
SHANGHAI, July 8, 2021 /PRNewswire/ -- Sequanta Technologies Co., Ltd. ("Sequanta") and Mission Bio. ("Mission Bio") are pleased to announce that they have entered into a strategic partnership, providing high-quality single-cell sequence services using Mission Bio's products to customers in mainl...
2021-07-09 15:44
2337
Nippon Express (India) Newly Acquires GDP Certification at Three Locations
TOKYO, July 8, 2021 /PRNewswire/ -- Nippon Express (India) Private Limited (hereinafter "NE India"), a local subsidiary of Nippon Express Co., Ltd., obtained Good Distribution Practice (GDP) certification in April for its temperature-controlled hubs inDelhi, Mumbai and Ahmedabad, evidencing the ...
2021-07-08 15:00
1677
BioShin Expands Senior Leadership Team: Sarah Lu Joins BioShin as Chief Medical Officer, Mary Ma Joins BioShin as Chief Commercial Officer
SHANGHAI, July 8, 2021 /PRNewswire/ -- BioShin Limited today announced the appointment of Dr.Zhihong (Sarah) Lu as Chief Medical Officer and Dr. Ma (Mary) Li as Chief Commercial Officer. Sarah will play a critical role in BioShin's clinical development of pipeline products inAsia-Pacific markets,...
2021-07-08 12:01
2669
Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis
* Both batoclimab 340 mg and 680 mg treatment groups demonstrated rapid, substantial and persistent clinical improvement over placebo * Favorable safety and tolerability profile with no serious adverse events (SAEs) and no adverse events (AEs) leading to discontinuation * Strong IgG reductio...
2021-07-06 21:06
18624
Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD
ADELAIDE, Australia, July 6, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a global, clinical stage biopharmaceutical company, is pleased to announce that it has initiated a Phase2b trial (the ATTUNE Study) to evaluate the tablet formulation of BNC210 in p...
2021-07-06 18:00
17779
Transcenta Provides Program Update for Anti-Claudin18.2 Monoclonal Antibody TST001 and Reports Promising Early Anti-Tumor Responses in Patients with Gastric Cancer
SUZHOU, China, July 2, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announces that promising anti-tumor response...
2021-07-02 21:02
3173
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 308 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 307 media titles]
2026-05-19 23:59
Hong Leong Bank Awarded Best Managed Bank in Malaysia by The Asian Banker, Group MD/CEO Kevin Lam Named Best Bank CEO in Malaysia
[Picked up by 293 media titles]
2026-05-15 17:00
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 289 media titles]
2026-05-18 15:30
AIMX Singapore 2026 Anchors Strategic Relationship with TechInnovation and AI Gravity
[Picked up by 279 media titles]
2026-05-19 14:00
Most Read
H World Group Reports Q1 Results, Highlighting Asset-light Growth and Expanding APAC Footprint
2026-05-15 20:11
7995
